CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Oncolytics Biotech Inc. (ONCY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Oncolytics Biotech Inc. (ONCY)

Pharmaceutical Preparations · market cap $88M · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-12
Conference
Pipeline
10
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Oncolytics Biotech (ONCY) is a San Diego-based, 28-employee clinical-stage company developing pelareorep (REOLYSIN), an intravenously delivered, unmodified reovirus isolate meant to lyse tumor cells selectively and turn 'cold' tumors inflamed through innate and adaptive immune activation. Our database lists a Phase 3 lead program in metastatic or recurrent squamous cell lung cancer plus about nine Phase 2 entries across anal, colorectal, lung and prostate cancers. The setup is dominated by balance-sheet stress: $4.1M of cash against a ~$60M market cap and a computed runway of about 1.5 months.
The catalyst path
  • 2026-12-12Conferenceimp 4/10
  • 2027-07-30 (est.)Phase 2 · Pelareorepimp 7/10
  • 2027-08-30 (est.)Phase 2 · Pelareorepimp 7/10
Pipeline
AssetPhaseIndication
PelareorepPhase 2Anal Cancer Metastatic
REOLYSINPhase 3Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
REOLYSIN®Phase 2Carcinoma, Non-small Cell Lung
Docetaxel, Reolysin and PrednisonePhase 2Prostate Cancer
Pemetrexed and Reolysin (and safety run-in)Phase 2Non Small Cell Lung Cancer
Trifluridine TipiracilPhase 2Anal Cancer Metastatic
Folfox plus Bevacizumab and reolysinPhase 2Colorectal Cancer
mFOLFIRINOX Treatment RegimenPhase 2Anal Cancer Metastatic
Docetaxel and ReolysinPhase 2Non Small Cell Lung Cancer
Folfox plus BevacizumabPhase 2Colorectal Cancer
Price & technical context
3-month
-56.0%
6-month
-53.8%
12-month
-65.7%
52-wk range
$0.37–$1.27
vs 50-day MA
-34.9%
vs 200-day MA
-55.2%
Realized vol
80.5%
Max drawdown
-74.0%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for ONCY (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.